GlassScriptPhysician profile
Mary B Heery
NPI 1134437049
$1,376.05
in general payments reported to CMS, 2019-2025
25 companies · $65.52 in 2025
The $65.52 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $385 · 2023: $692 · 2024: $116 · 2025: $65.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $254.87 | 2021-2025 | Pomalyst, Opdivo, Abecma |
| Janssen Biotech, INC. | $123.71 | 2022-2023 | Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $104.37 | 2023 | |
| Genentech, INC. | $103.94 | 2023 | Phesgo |
| E.R. Squibb & Sons, L.L.C. | $78.94 | 2021-2025 | Opdivo |
| Genentech USA, INC. | $71.90 | 2023 | Phesgo, Alecensa, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $69.48 | 2022-2023 | Libtayo |
| Array Biopharma INC | $66.85 | 2023 | Braftovi, Lorbrena, Paxlovid |
| Eisai INC. | $63.09 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $54.26 | 2021-2023 | Enhertu |
| Lilly USA, LLC | $52.74 | 2021-2022 | |
| Gilead Sciences, INC. | $46.44 | 2022-2023 | |
| Sobi, INC | $40.88 | 2023 | |
| Jazz Pharmaceuticals INC. | $34.34 | 2022 | |
| Coherus Oncology, INC. | $30.23 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $22.98 | 2023 | Myrisk |
| Amgen INC. | $21.00 | 2023 | Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $20.21 | 2023 | Epkinly, Imbruvica |
| Astellas Pharma US INC | $19.95 | 2023 | Padcev |
| Glaxosmithkline, LLC. | $18.68 | 2022 | |
| Daiichi Sankyo INC. | $16.05 | 2022 | |
| Genzyme Corporation | $14.60 | 2022 | |
| Abbvie INC. | $14.21 | 2023 | |
| Puma Biotechnology, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Heery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.